Clovis Oncology (CLVS) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. KLAC
9. BIIB
10. ETSY

Go back to Clovis Oncology (CLVS) Misses Q3 EPS by 11c

Clovis Oncology Announces Third Quarter 2018 Operating Results

October 30, 2018 4:05 PM EDT

$22.8M in Rubraca® sales for the third quarter of 2018 compared to $16.8M for Q3 2017 Free drug increased to 30 percent of overall commercial supply, equivalent to $9.6 million in commercial value Initial TRITON2 data for Rubraca in mCRPC presented at ESMO include 44% confirmed ORR and 51% confirmed PSA response rate in 25 RECIST-evaluable and 45 PSA-evaluable patients with a BRCA1/2 alteration; preliminary safety data are consistent with those observed in other Rubraca studies $604.4 million in cash, cash equivalents and available for sale securities at September 30, 2018... More